COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge.
作者信息
Cochran Willa, Shah Pali, Barker Lindsay, Langlee Julie, Freed Kristin, Boyer Lauren, Scott Anderson R, Belden Maura, Bannon Jaclyn, Kates Olivia S, Permpalung Nitipong, Mostafa Heba, Segev Dorry L, Brennan Daniel C, Avery Robin K
机构信息
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Comprehensive Transplant Center, Johns Hopkins University School of Medicine, Baltimore, MD.
出版信息
Transplantation. 2022 Jul 1;106(7):e346-e347. doi: 10.1097/TP.0000000000004162. Epub 2022 Apr 11.
Abstract
摘要
相似文献
1
COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge.奥密克戎毒株激增期间实体器官移植受者的新冠病毒疾病临床结局
Transplantation. 2022 Jul 1;106(7):e346-e347. doi: 10.1097/TP.0000000000004162. Epub 2022 Apr 11.
2
Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.COVID-19 治疗药物在实体器官移植受者中的应用进展，包括奥密克戎变异株。
Transplantation. 2022 Aug 1;106(8):1528-1537. doi: 10.1097/TP.0000000000004200. Epub 2022 Jul 22.
3
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
4
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.奥密克戎变异株流行期间，实体器官移植受者中可获得的门诊 COVID-19 治疗的真实世界经验。
Am J Transplant. 2022 Oct;22(10):2458-2463. doi: 10.1111/ajt.17098. Epub 2022 May 30.
5
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?新冠疫情能否改善实体器官移植受者的管理？
Viruses. 2022 Aug 24;14(9):1860. doi: 10.3390/v14091860.
6
Is the Omicron variant truly less virulent in solid organ transplant recipients?奥密克戎变异株是否确实在实体器官移植受者中毒力较弱？
Transpl Infect Dis. 2022 Dec;24(6):e13923. doi: 10.1111/tid.13923. Epub 2022 Aug 12.
7
Immunosuppression in solid organ transplant recipients with Covid-19: More data, but still complicated.实体器官移植受者 COVID-19 中的免疫抑制：更多数据，但仍复杂。
Transpl Infect Dis. 2021 Aug;23(4):e13650. doi: 10.1111/tid.13650. Epub 2021 Jul 29.
8
Omicron Infections in Vaccinated Pediatric Solid Organ Transplant Recipients.接种疫苗的儿科实体器官移植受者中的奥密克戎感染。
J Pediatric Infect Dis Soc. 2024 Feb 26;13(2):152-154. doi: 10.1093/jpids/piad108.
9
Prior Infection Reduces Omicron COVID-19 Severity in Solid Organ Transplant Recipients.既往感染可降低实体器官移植受者感染奥密克戎毒株所致新冠的严重程度。
Transplantation. 2024 May 1;108(5):1070-1071. doi: 10.1097/TP.0000000000004905. Epub 2024 Jan 31.
10
COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination.实体器官移植受者接种SARS-CoV-2疫苗后感染新冠病毒
Am J Transplant. 2021 Oct;21(10):3496-3499. doi: 10.1111/ajt.16618. Epub 2021 May 18.
引用本文的文献
1
Risk factor analysis and outcomes of heart transplant recipients infected by COVID-19.新冠病毒感染的心脏移植受者的危险因素分析及预后
Front Immunol. 2025 Jul 30;16:1597333. doi: 10.3389/fimmu.2025.1597333. eCollection 2025.
2
Long-Term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation.肾移植受者接种 SARS-CoV-2 疫苗后的长期免疫反应及突破性感染风险
Vaccines (Basel). 2025 May 26;13(6):566. doi: 10.3390/vaccines13060566.
3
Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients.揭示白细胞介素-2和白细胞介素-5在肾移植受者中针对严重急性呼吸综合征冠状病毒2特异性T细胞反应中的意义。
Npj Viruses. 2024 Feb 14;2(1):7. doi: 10.1038/s44298-024-00015-7.
4
Incidence and severity of SARS-CoV-2 infection in lung transplant recipients in the Omicron era.奥密克戎时代肺移植受者中新型冠状病毒2型感染的发病率和严重程度。
JHLT Open. 2023 Sep 20;1:100004. doi: 10.1016/j.jhlto.2023.100004. eCollection 2023 Oct.
5
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future.单克隆抗体在肺移植受者预防和早期治疗 COVID-19 中的应用：一项系统综述及对单克隆抗体未来作用的展望
Transpl Int. 2025 Feb 10;38:13800. doi: 10.3389/ti.2025.13800. eCollection 2025.
6
Impact of Bebtelovimab Treatment Timing on COVID-19 Outcomes in Ambulatory Solid Organ Transplant Recipients.比贝妥洛单抗治疗时机对门诊实体器官移植受者新冠病毒病结局的影响
Transpl Infect Dis. 2025 Jan-Feb;27(1):e14405. doi: 10.1111/tid.14405. Epub 2024 Nov 16.
7
Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience.COVID-19 肾移植门诊患者的管理：单中心经验。
Transpl Int. 2024 Sep 26;37:12920. doi: 10.3389/ti.2024.12920. eCollection 2024.
8
Risk factors for severe outcomes of coronavirus disease 2019 through the waves of the pandemic: Comparing patients with and without solid organ transplantation.通过疫情的波次比较合并和未合并实体器官移植的 COVID-19 患者严重结局的危险因素。
Transpl Infect Dis. 2024 Oct;26(5):e14333. doi: 10.1111/tid.14333. Epub 2024 Jul 9.
9
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.mRNA 疫苗接种后肾移植受者对 SARS-CoV-2 奥密克戎亚变种的中和抗体反应和细胞反应。
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
10
Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France.免疫功能低下者在新冠疫情期间的生活：来自法国的患者与医生视角
Infect Dis Ther. 2024 Mar;13(3):439-445. doi: 10.1007/s40121-024-00941-2. Epub 2024 Mar 8.
Zotero 插件